The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.
Although revenues from the firm's global diagnostics business were down 6 percent year over year, molecular diagnostic product revenues were up 6 percent.
In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.
The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.
The firm said that sales growth was impacted by immigration headwinds, severe winter weather in the US, and unfavorable order timing in Asia.
The company said revenues in its diagnostics business unit rose 62 percent during the quarter.